Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine

Vas Narasimhan, Novartis CEO, joins ‘Squawk on the Street’ to discuss the company’s positive Leukemia drug results, the review timeline for Scemblix, and insights into Novartis’ breast cancer drug.